Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation

European Journal of Cardio-thoracic Surgery

Volumn 10, Issue 1, 1996, Pages 54-60

  Ovrum E ^a   Fosse, E ^b   Mollnes, T E ^c   Am Holen E ^a   Tangen, G ^a   Abdelnoor, M ^a   Ringdal, M A L ^a   Oystese R ^a   Venge, P ^d  

^a Oslo Heart Center   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NORDLAND HOSPITAL   (Norway)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiopulmonary bypass; Complement; Granulocytes; Heparin coated

Indexed keywords

HEPARIN; LACTOFERRIN; PEROXIDASE;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; ELECTIVE SURGERY; FEMALE; GRANULOCYTE; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CARDIOPULMONARY BYPASS; COMPLEMENT ACTIVATION; CORONARY ARTERY BYPASS; FEMALE; GRANULOCYTES; HEPARIN; HUMANS; LACTOFERRIN; MALE; MIDDLE AGED; PEROXIDASE; PROSPECTIVE STUDIES; SURGICAL PROCEDURES, ELECTIVE;

EID: 0029691892     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1010-7940(96)80266-1     Document Type: Article

References (35)

1. Borowiec J, Thelin S, Bagge L, Hullman J, Hansson H-E (1992) Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. Scand J Thorac Cardiovasc Surg 26:177-185
2. Borowiec J, Thelin S, Bagge L, Nilsson L, Venge P, Hansson HE (1992) Heparin-coated circuits reduce activation of granulocytes during cardiopulmonary bypass. J Thorac Cardiovasc Surg 104:642-647
3. Chenoweth DE, Cooper SW, Hugli TE, Stewart RW, Blackstone EH, Kirklin JW (1981) Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. N Engl J Med 304:497-503
4. Cheung AK, Lewinther M, Chenoweth DE, Lew WYW, Henderson LW (1986) Cardiopulmonary effects of cuprophane-activated plasma in the swine. Kidney Int 29:799-806
5. Deppisch R, Schmitt V, Sommer J, Hansch GM, Ritz E, Rauterberg EW (1990) Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int 37:696-706
6. Fosse E, Moen O, Johnson E, Semb G, Brockmeier V, Mollnes TE, Fagerhol M, Venge P (1994) Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 58:472-477
7. Garred P, Mollnes TE, Lea T (1988) Quantification of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol 27:329-335
8. Gillinov AM, Devaleria PA, Winkelstein JA, Wilson I, Curtis WE, Shaw D, Yeh CG, Rudolph AR, Baumgartner WA, Herskowitz A, Cameron DE (1993) Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg 55:619-624
9. Gott V, Whiffen JD, Datton RC (1963) Heparin bonding on colloidal graphite surfaces. Science 142:1297-1298
10. Gu YJ, Van Oeveren W, Van der Kamp KWHJ, Akkerman C, Boonstra PW, Wildewuur CRH (1991) Heparin-coating of extracorporeal circuits reduces thrombin formation in patients undergoing cardiopulmonary bypass. Perfusion 6:221-225
11. Gu YJ, Van Oeveren W, Akkerman C, Boonstra PW, Huyzen RJ, Wildevuur CRH (1993) Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 55:917-922
12. Hammerschmith DE, Srtoncek DF, Bowers TK (1981) Complement activation and neutropenia occurring during cardiopulmonary bypass. J Thorac Cardiovasc Surg 81:370-377
13. Havermann K, Gramse M (1984) Physiology and pathophysiology of neutral proteinases of human granulocytes. In Hörl WH, Heidland A (eds) Proteinases. potential role in health and disease. Plenum Press, New York; pp 1-20
14. Horrow JC (1985) Protamine: A review of its toxicity. Anesth Analg 64:348-361
15. Hsu LC (1991) Principles of heparin-coating techniques. Perfusion 6:209-219
16. Kirklin JK, Kirklin JW (1990) Cardiopulmonary bypass for cardiac surgery. In: Sabiston DC Jr, Spencer FC (eds) Surgery of the Chest. Saunders, Philadelphia, pp 1107-1125
17. Kirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD (1983) Complement and the damaging effects of cardiopulmonary bypass J Thorac Cardiovasc Surg 86:845-857
18. Kleinbaum D, Kuyper L, Morgenstein H (1982) Epidemiologic research. Principles and quantitative methods. Van Nostrand Reinhold, New York, pp 141-157
19. Larm O, Larsson R, Olsson P (1983) A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Dev Art Org 11:161-173
20. Matthews JNS, Altman DG, Campell MJ, Royston P (1990) Analysis of serial measurements in medical research. Br Med J 300:230-235
21. Mollnes TE, Lea T, Frøland SS, Harboe M (1985) Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 22:197-202
22. Mollnes TE, Videm V, Riesenfeld J (1991) Complement activation and bioincompatibility. The terminal complement complex for evaluation, and surface modification with heparin for improvement of biomaterials. Clin Exp Immunol 88 (Suppl 1):21-26
23. Nilsson L, Nilsson U, Venge P, Johansson O, Tydén, Åberg T, Nystrøm S-O (1990) Inflammatory system activation during cardiopulmonary bypass as an indicator of biocompatibility: a randomized comparison of bubble and membrane oxygenators. Scand J Thorac Cardiovasc Surg 24:53-58
24. Øvrum E, Åm Holen E, Abdelnoor M, Øystese R (1991) Conventional blood conservation techniques in 500 consecutive coronary artery bypass operations. Ann Thorac Surg 52 500-505
25. Øvrum E, Lindberg H, Åm-Holen E, Abdelnoor M, Bech J (1991) Systemic and pulmonary circulatory effects of protamine following cardiopulmonary bypass in man. Scand J Thorac Cardiovasc Surg 25 19-24
26. Pekna M, Hagman L, Haldèn E, Nilsson UR, Nilsson B, Thelin S (1994) Complement activation during cardiopulmonary bypass. effect of immobilized heparin. Ann Thorac Surg 58:421-424
27. Riegel W, Spillner G, Schlosser V, Hörl W (1988) Plasma levels of main granulocyte components during cardiopulmonary bypass J Thorac Cardiovasc Surg 95:1014-1019
28. Steinberg JB, Kapelanski DP, Olson JD, Weiler JM (1993) Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 106:1008-1016
29. Svennevig JL, Geiran OR, Karlsen H, Pedersen T, Mollnes TE, Kongsgaard U, Frøysaker T (1993) Complement activation during extracorporeal circulation In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 106:466-472
30. Venge P, Hällgren R. Stålenheim G, Olsson I (1979) Effects of serum and cations on the selective release of granular proteins from human neutrophils during phagocytosis. Scand J Haematol 22:317-326
31. Venge P, Nilsson L, Nystrøm SO, Aberg T (1987) Serum and plasma measurements of neutrophil granule proteins during cardiopulmonary bypass; a model to estimate human turnover of lactoferrin and myeloperoxidase Eur J Haematol 39:339-345
32. Videm V, Mollnes TE, Garred P, Svennevig JL (1991) Biocompatibility of extracorporeal circulation: In vitro comparison of heparin-coated and uncoated oxygenator circuits. J Thorac Cardiovasc Surg 101:654-660
33. Videm V, Nilsson L, Venge P, Svennevig JL (1991) Reduced granulocyte activation with a heparin-coated device in an in vitro model of cardiopulmonary bypass. Artif Organs 15:90-95
34. Videm V, Svennevig JL, Fosse E, Semb G, Østerud A, Mollnes TE (1992) Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 103:806-813
35. Von Segesser LK, Weiss BM, Garcia E, von Felten A, Turina MI (1992) Reduction and elimination of systemic heparinization during cardiopulmonary bypass. J Thorac Cardiovasc Surg 103:790-799